Drug Trial Radar · NCT06685835
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
214
Actual
Start
Dec 16, 2024
Primary completion
Feb 12, 2026
Study completion Jun 8, 2026
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
Conditions
- Hidradenitis Suppurativa
Interventions
BrensocatibDrug
Film-coated Oral tablet
PlaceboDrug
Film-coated Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Week 16Time frame: Baseline and Week 16
Locations
72 sites in 10 countries. Site status is shown where the registry gives one.
USA001
Phoenix, Arizona
USA007
Sacramento, California
USA026
Coral Gables, Florida
USA027
Hollywood, Florida
USA021
Margate, Florida
USA018
Miami, Florida
USA025
Ocala, Florida
USA004
Tampa, Florida
USA010
Weston, Florida
USA028
Atlanta, Georgia
USA011
Sandy Springs, Georgia
USA003
Plainfield, Indiana
USA002
Baton Rouge, Louisiana
USA017
Boston, Massachusetts
USA012
Detroit, Michigan
USA024
Fort Gratiot, Michigan
USA020
Minneapolis, Minnesota
USA015
St Louis, Missouri
USA013
Lebanon, New Hampshire
USA009
Cleveland, Ohio
USA016
Springfield, Ohio
USA019
Hershey, Pennsylvania
USA022
Philadelphia, Pennsylvania
USA005
Dallas, Texas
USA023
Dallas, Texas
USA008
Spokane, Washington
AUS003
Darlinghurst, New South Wales, Australia
AUS004
Kogarah, New South Wales, Australia
AUS001
Brisbane, Queensland, Australia
AUS006
Woolloongabba, Queensland, Australia
AUS002
Fremantle, Western Australia, Australia
BGR001
Lovech, Bulgaria
BGR003
Pleven, Bulgaria
BGR004
Sofia, Bulgaria
BGR002
Stara Zagora, Bulgaria
CAN004
Québec, Canada
CAN003
Barrie, Ontario, Canada
CAN006
Guelph, Ontario, Canada
CAN007
Peterborough, Ontario, Canada
CAN011
Richmond Hill, Ontario, Canada
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.